Board Chair

David Chang, M.D., Ph.D.

David D. Chang is a co-founder and Chairman of the Board of Directors of IconOVir Bio. He is a co-founder and currently serves as the President and Chief Executive Officer of Allogene Therapeutics, Inc. (ALLO), a clinical stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. David previously served as Executive Vice President, Research & Development, and Chief Medical Officer of Kite Pharma, Inc., prior to its acquisition by Gilead Sciences in October 2017. He has an industry-leading track record of innovation in the field of oncology drug development, including the development for Yescarta (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma. From 2002 to 2014, he held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology. During this time, David spearheaded personalized therapy strategies that underlie the success of Vectibix® (panitumumab). He also provided therapeutic area leadership to pivotal programs for Blincyto® (blinatumomab) a bispecific T cell engager antibody in acute lymphocytic leukemia and for IMLYGIC (talimogene laherparepvec), a first-of-its-kind oncolytic immunotherapy, in melanoma. 

Prior to joining Amgen, David held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He obtained a B.S. degree in Biology from the Massachusetts Institute of Technology and M.D. and Ph.D. degrees from Stanford University. David completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow. David serves on the Board at Notch Therapeutics and as a member of the scientific advisory board at Kronos Bio, Inc. (KRON). He is also a scientific advisor at Vida Ventures, LLC and a venture partner at Two River.